A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT02078609
- Locations
- 🇳🇱
Novartis Investigative Site, Amsterdam, Netherlands
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- Conditions
- Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies
- Interventions
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 291
- Registration Number
- NCT02074839
- Locations
- 🇺🇸
Moffit Cancer Center, Tampa, Florida, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic-AZ, Phoenix, Arizona, United States
Study of the Glutaminase Inhibitor CB-839 in Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)
- Interventions
- Drug: CB-Aza
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT02071927
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 367
- Registration Number
- NCT02039726
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 204
- Registration Number
- NCT02013648
- Locations
- 🇦🇹
Universitätsklinik für Innere Medizin V, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02003573
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Washington School of Medicine, Saint Louis, Missouri, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 30
- Registration Number
- NCT01999413
- Locations
- 🇫🇷
Emmanuel GYAN, Tours, France
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)MyelodysplasiaChronic Lymphocytic LeukemiaMarginal Zone B-Cell LymphomaFollicular LymphomaNon-Hodgkin LymphomaMultiple MyelomaChronic Myelogenous LeukemiaPlasma Cell Leukemia
- Interventions
- Radiation: Total Body IrradiationDrug: Mycophenylate mofetilBiological: Umbilical cord blood
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 200
- Registration Number
- NCT01962636
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
- Conditions
- Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 703
- Registration Number
- NCT01929408
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 50
- Registration Number
- NCT01912274
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Ctr, Duarte, California, United States
🇺🇸USC Norrris Cancer Center, Los Angeles, California, United States
🇺🇸Bay Area Cancer Research Group, Pleasant Hill, California, United States